Roche Holding (1ROG) Stock Overview
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
1ROG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Roche Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 378.00 |
| 52 Week High | CHF 414.00 |
| 52 Week Low | CHF 258.00 |
| Beta | 0.21 |
| 1 Month Change | -5.97% |
| 3 Month Change | 13.17% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 76.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1ROG | IT Pharmaceuticals | IT Market | |
|---|---|---|---|
| 7D | -6.4% | -5.4% | -6.4% |
| 1Y | n/a | -3.2% | 14.0% |
Return vs Industry: Insufficient data to determine how 1ROG performed against the Italian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 1ROG performed against the Italian Market.
Price Volatility
| 1ROG volatility | |
|---|---|
| 1ROG Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IT Market | 7.4% |
| 10% least volatile stocks in IT Market | 2.7% |
Stable Share Price: 1ROG's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: 1ROG's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1896 | 103,249 | Thomas Schinecker | www.roche.com |
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions.
Roche Holding AG Fundamentals Summary
| 1ROG fundamental statistics | |
|---|---|
| Market cap | €302.29b |
| Earnings (TTM) | €14.28b |
| Revenue (TTM) | €70.24b |
Is 1ROG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1ROG income statement (TTM) | |
|---|---|
| Revenue | CHF 63.36b |
| Cost of Revenue | CHF 16.16b |
| Gross Profit | CHF 47.19b |
| Other Expenses | CHF 34.31b |
| Earnings | CHF 12.88b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 23, 2026
| Earnings per share (EPS) | 16.19 |
| Gross Margin | 74.49% |
| Net Profit Margin | 20.33% |
| Debt/Equity Ratio | 83.5% |
How did 1ROG perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/06 04:38 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Roche Holding AG is covered by 46 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Staszak | Argus Research Company |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Emily Field | Barclays |